Galectin Therapeutics provides final randomization status of NAVIGATE

Galectin Therapeutics announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis, NASH. The last patient was randomized into NAVIGATE at the end of February 2023. NAVIGATE has randomized 357 patients, above its initial objective of approximately 315 patients. NAVIGATE is the first study of its kind and is a global effort that recruited patients in 14 countries and on five continents. The main efficacy objective is the primary prevention of esophageal varices. Joel Lewis, the Company’s President and Chief Executive Officer said: "We are gratified to reach this important milestone. The last randomization will allow us to focus on efficiently executing our program and other stated goals for the rest of the year. On behalf of the whole team at Galectin Therapeutics, I again want to personally thank our investigators and their teams, along with all of the patients in the trial, for participating in this innovative study. I also am extremely grateful for the commitment and dedication of all of our employees in enabling us to reach this milestone."